Novo Nordisk reported DKK119.17B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Bausch Health Companies USD 19.9B 720M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Merck USD 46.67B 77M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Novo Nordisk DKK 119.17B 231M Mar/2026
Novo Nordisk DKK 14.02B 224.49M Sep/2025
Pacira USD 367.66M 4.53M Mar/2026
Sanofi EUR 13.84B 1.88B Mar/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022